ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:15:00 2024-05-03 pm EDT			5-day change	1st Jan Change
9.15 ^USD	+2.01%		+24.49%	+82.27%

12:56pm	Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline	MT
May. 02	Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types	CI

U.S. FDA approves ImmunityBio's bladder cancer therapy

April 22, 2024 at 06:25 pm EDT

April 22 (Reuters) - The U.S. FDA approved ImmunityBio's combination therapy to treat a type of bladder cancer, the regulator said on Monday, which would help bring the company's first product to market. (Reporting by Puyaan Singh and Pratik Jain in Bengaluru; Editing by Shailesh Kuber)

Latest news about ImmunityBio, Inc.

Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline	06:56am	MT
Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types	May. 02	CI
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline	Apr. 30	MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating	Apr. 29	MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	Apr. 29	MT
Transcript : ImmunityBio, Inc. - Special Call	Apr. 26
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	Apr. 25	CI
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer	Apr. 23	MT
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	Apr. 23	MT
Top Premarket Gainers	Apr. 23	MT
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva	Apr. 23	DJ
US FDA approves ImmunityBio's bladder cancer therapy	Apr. 22	RE
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	Apr. 22	CI
U.S. FDA approves ImmunityBio's bladder cancer therapy	Apr. 22	RE
ImmunityBio Files Mixed Shelf	Apr. 17	MT
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating	Mar. 25	MT
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
ImmunityBio Announces Data from A Phase 1 Pilot Study	Mar. 05	CI
ImmunityBio Says Cancer Vaccine Trial Moving to Controlled Phase	Feb. 21	MT
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	Feb. 21	CI
Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG	Feb. 05	CI
US Equity Markets Close Lower Tuesday Ahead of Fed Meeting Minutes	Jan. 02	MT
Sector Update: Health Care Stocks Gain Late Afternoon	Jan. 02	MT

Chart ImmunityBio, Inc.

Duration

Period

More charts

Company Profile

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

Sector

Biotechnology & Medical Research

Calendar

02:00pm - American Urological Association Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ImmunityBio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.97 USD

Average target price

7.5 USD

Spread / Average Target

-16.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNITYBIO, INC.	+82.27%	6.07B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B
ARGENX SE	+4.40%	23.07B
BIONTECH SE	-12.15%	22.23B
GENMAB A/S	-4.36%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.04%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B

Bio Therapeutic Drugs